Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-α-2a

Antiviral Research

Volumn 81, Issue 1, 2009, Pages 88-91

  Chen, Jinjun ^a   Wang, Zhanhui ^a   Guo, Yabing ^a   Peng, Jie ^a   Sun, Jian ^a   Ahmed, Choudhary Shoaib ^a   Zhou, Yuanping ^a   Hou, Jinlin ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adefovir; Chronic hepatitis B; Hepatitis B surface antigen; Peg interferon 2a

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASSAY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; VIRAL LOAD;

EID: 57149120288     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.09.005     Document Type: Article

References (22)

1. Chen C.H., Lee C.M., Wang J.H., Tung H.D., Hung C.H., and Lu S.N. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur. J. Gastroenterol. Hepatol. 16 (2004) 1213-1218
2. Colombatto P., Civitano L., Bizzarri R., Oliveri F., Choudhury S., Gieschke R., Bonino F., and Brunetto M.R. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antiviral Ther. 11 (2006) 197-212
3. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., Iinuma K., and Mushahwar I.K. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J. Virol. Methods 115 (2004) 217-222
4. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., and Brosgart C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348 (2003) 800-807
5. Hess G., Gerlich W., Gerken G., Manns M., Hutteroth T.H., and Meyer zum Büschenfelde K.H. The effect of recombinant alpha-interferon treatment on serum levels of hepatitis B virus-encoded proteins in man. Hepatology 7 (1987) 704-708
6. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
7. Janssen H.L., Kerhof-Los C.J., Heijtink R.A., and Schalm S.W. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res. 23 (1994) 251-257
8. Kohmoto M., Enomoto M., Tamori A., Habu D., Takeda T., Kawada N., Sakaguchi H., Seki S., Shiomi S., and Nishiguchi S. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J. Med. Virol. 75 (2005) 235-239
9. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., McCloud P., and Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352 (2005) 2682-2695
10. Mao Y.M., Zeng M.D., Yao G.B., Ren H., Chen Y., Xu D., Chen Y., and Barker K.F. Efficacy and Safety of 4 Years Adefovir Dipivoxil (ADV) 10 mg in Chinese HBeAg Positive Chronic Hepatitis B (CHB) (2008), APASL, Seoul, Korea (poster number: pp009)
11. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., Jeffers L., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., and Brosgart C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348 (2003) 808-816
12. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., Lu Z.M., Piratvisuth T., Germanidis G., Yurdaydin C., Diago M., Gurel S., Lai M.Y., Button P., and Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351 (2004) 1206-1217
13. Marcellin P., Bonino F., Lau G., Farci P., Yurdaydin C., Piratvisuth T., Lu K., Gurel S., Hadziyannis S., Wang Y., and Popescu M. Virological and biochemical response in patients with hbeag-negative CHB treated with peginterferon alpha-2a (40 kD) ± lamivudine: 3-year follow-up results. J. Hepatol. 46 (2007) S25-S26
14. Mihm U., Gärtner B.C., Faust D., Hofmann W.P., Sarrazin C., Zeuzem S., and Herrmann E. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J. Hepatol. 43 (2005) 217-224
15. Peters M.G., Hann H.H., Martin P., Heathcote E.J., Buggisch P., Rubin R., Bourliere M., Kowdley K., Trépo C., Gray D.D., Sullivan M., Kleber K., Ebrahimi R., Xiong S., and Brosgart C.L. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
16. Rang A., Günther S., and Will H. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J. Hepatol. 31 (1999) 791-799
17. ter Borg M.J., van Zonneveld M., Zeuzem S., Senturk H., Akarca U.S., Simon C., Hansen B.E., Haagmans B.L., de Man R.A., Schalm S.W., and Janssen H.L. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 44 (2006) 721-727
18. Tsiang M., Rooney J.F., Toole J.J., and Gibbs C.S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29 (1999) 1863-1869
19. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., Trépo C., Marcellin P., Goodman Z., Delaney W.E., Xiong S., Brosgart C.L., Chen S.S., Gibbs C.S., and Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004) 1750-1758
20. Wong D.K., Yuen M.F., Ngai V.W., Fung J., and Lai C.L. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antiviral Ther. 11 (2006) 909-916
21. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., Longerich T., Schirmacher P., Metzler F., Zankel M., Fischer C., Currie G., Brosgart C., and Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44 (2006) 675-684
22. Zeng M., Mao Y., Yao G., Wang H., Hou J., Wang Y., Ji B.N., Chang C.N., and Barker K.F. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 44 (2006) 108-116